Owkin Announces Collaboration with Bristol Myers Squibb


Owkin announced that it has entered into a multi-year, strategic collaboration with Bristol Myers Squibb to apply Owkin’s Artificial Intelligence (AI) capabilities to design clinical trials for Bristol Myers Squibb. The collaboration will initially focus on cardiovascular diseases, and has the potential to extend into projects in other therapeutic areas.

Read more about the collaboration here.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.